---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-021435"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:21:58.047677+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eton enters stalking horse bid to acquire Wellstat assets for $37M; sells royalty interests for $5.5M

## Summary
- Eton named stalking horse bidder to acquire commercial assets of Wellstat Therapeutics & Biologics for $37M via bankruptcy auction.
- Closing is uncertain and subject to the auction process; Eton has cash on hand and committed financing to complete the deal if successful.
- Eton amended its 2020 Asset Purchase Agreement with Azurity Pharmaceuticals, agreeing to sell back royalty interests for $5.5M in cash.
- The $5.5M from Azurity provides near-term liquidity; proceeds are included in Eton's available funds for the potential Wellstat acquisition.

## SEC filing metadata
- accession: 0001493152-23-021435
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/0001493152-23-021435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-021435
- JSON: https://secwatch.observer/filing/0001493152-23-021435.json
- Plain text: https://secwatch.observer/filing/0001493152-23-021435.txt

## Key facts
- Material Agreements
  Eton Pharmaceuticals, Inc. amended a asset purchase with Azurity Pharmaceuticals, Inc. valued at $5.5 million (effective 2023-06-15).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Azurity Pharmaceuticals, Inc.
  - Value: $5.5 million
  - Effective: 2023-06-15
  source text: Also, on June 15, 2023, the Company entered into an amendment to the Asset Purchase Agreement dated December 31, 2020 (the “Original Agreement”) by and between the Company and Azurity Pharmaceuticals, Inc. (“Azurity”). Under the amendment, the Company will sell back to Azurity the royalty interests it received under the Original Agreement for a total consideration of $5.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/0001493152-23-021435-index.htm
- Material Agreements
  Eton Pharmaceuticals, Inc. entered into Asset Purchase Agreement with Wellstat Therapeutics Corporation, Wellstat Biologics Corporation, Janet M. Nesse, as Bankruptcy Trustee, and certain other affiliates valued at $37 million (effective 2023-06-09).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Wellstat Therapeutics Corporation, Wellstat Biologics Corporation, Janet M. Nesse, as Bankruptcy Trustee, and certain other affiliates
  - Value: $37 million
  - Effective: 2023-06-09
  source text: On June 9, 2023, Eton Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors, whereby the Company was named the “stalking horse bidder” in the bankruptcy proceedings of the Debtors and agreed to acquire the commercial assets of the Debtors for consideration of $37 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223021435/0001493152-23-021435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.